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Abstract: Anti-TNFα medications have led to vast improvements in the treatment of 
inflammatory conditions, including rheumatoid arthritis and Crohn’s disease. As these diseases 
often afflict women in their reproductive years, the safety of these drugs during pregnancy is 
an important issue. Prospectively collected data thus far appear to be reassuring; however an 
analysis of the FDA-reported anomalies has raised some questions. It appears that significant 
levels of these drugs cross the placenta as the pregnancy nears term, but little is passed through 
breast milk. Prior to using these medications during pregnancy, the risks and benefits of these 
drugs, other treatment options, and the ongoing inflammatory condition all must be carefully 
weighed by both doctor and patient.
Keywords: pregnancy, anti-TNFα medications, rheumatoid arthritis, Crohn’s disease, tera-
togenesis
Introduction
Anti-tumor necrosis factor α (TNFα) medications have revolutionized the treatment 
of inflammatory arthritis. When the first biologic drugs for arthritis, infliximab and 
etanercept, were approved by the Food and Drug Administration (FDA) in 1999, they 
raised the hopes for a life without pain and disability for many patients. Our standards 
for acceptable joint inflammation increased dramatically, no longer expecting patients 
to have chronic inflammation and damage but now modifying treatment with the goal 
of eliminating active arthritis.
Many patients with inflammatory arthritis, especially rheumatoid arthritis, are 
women in their reproductive years. These women maintain fertility and often wish 
to build families of similar size to women without arthritis. With increasing use of 
anti-TNFα drugs to treat arthritis in young women, questions about the safety of these 
agents for the developing fetus and breastfed infant have arisen. Animal data regarding 
pregnancy are benign, earning these agents an FDA Pregnancy Classification of B, 
meaning no animal reproductive concerns but limited human data. Human data are 
slowly being accumulated and published, with largely reassuring results. It does appear, 
however, that significant amounts of anti-TNFα medication cross the placenta in the 
third trimester.
This review will detail the human clinical data for pregnancy outcomes and fetal 
health following anti-TNFα medication exposure. In addition, it will discuss lactation 
during anti-TNFα medication use.International Journal of Women’s Health 2010:2 200
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Clinical utility of anti-TNFα 
medications
Anti-TNFα medications have decreased pain, joint erosions, 
and disability in many people with inflammatory arthritis. 
In rheumatoid arthritis (RA), these drugs dramatically slow 
the accumulation of radiographic damage. Studies show that 
the most clinical benefit is derived from the combination 
of anti-TNFα medications and methotrexate; alone, anti-
TNFα medications or methotrexate have similar degrees of 
benefit.1 Of patients taking the combination of infliximab 
plus methotrexate, over 60% will get 20% better, about 
50% will get 50% better, and over 30% will get 70% better. 
Between 10% and15% will even get 90% better.1 All of 
the anti-TNFα medications perform similarly with roughly 
equivalent improvement across studies.2
Anti-TNFα medications are typically indicated when 
inflammation from rheumatoid arthritis or psoriatic arthritis 
can not be controlled with oral agents, including methotrex-
ate, hydroxychloroquine, or sulfasalazine. In clinical practice 
in the United States, an estimated 40% of patients with 
long-standing rheumatoid arthritis and 25% with early RA 
(3 years duration) are taking anti-TNFα medications, 70% 
of the time with another disease-modifying antirheumatic 
drug (DMARD).3
During pregnancy, the options for arthritis therapy are 
limited. Both methotrexate and leflunomide are FDA Class 
X during pregnancy, indicating that the fetal risk outweighs 
any benefit to the mother. Methotrexate is a known teratogen 
and cessation of this drug is recommended 3 months prior to 
conception. The reported number of pregnancies exposed to 
the low weekly dose used in rheumatology is small, however. 
In a recent review of 6 reports including a total of 101 preg-
nancies, of those not electively terminated, 23% resulted in 
a miscarriage, and 66% in a live birth. Only 5 had a minor 
neonatal malformation.4 A report of prospectively collected 
pregnancies in women taking leflunomide at the time of con-
ception shows a low rate of congenital anomalies (5%) that 
is comparable to prospectively collected rheumatoid arthritis 
and healthy control pregnancies.5 Despite these findings, it is 
still recommended that women discontinue these medications 
prior to conception.
The use of NSAIDs during pregnancy is typically 
restricted to occasional use in the first half of pregnancy. 
Use in the third trimester can cause premature closure of the 
ductus arteriosis. NSAIDs may also promote oligohydram-
nios (low amniotic fluid levels) by restricting fetal renal 
blood flow. For this reason, most women are encouraged 
to take acetaminophen for pain during pregnancy. This, 
however, is often ineffective for the pain of inflammatory 
arthritis.
Medications considered relatively safe in pregnancy 
include corticosteroids, sulfasalazine, and hydroxychlo-
roquine. Prednisone can promote maternal hypertension, 
diabetes, and excessive weight gain, all significant problems 
during pregnancy. It may also lead to a lower birth weight 
and preeclampsia.6,7 Sulfasalazine is considered relatively 
safe during pregnancy and can be continued.7 Hydroxychlo-
roquine is also relatively safe, though less effective in treating 
inflammatory arthritis.7
With medications limited during pregnancy, the anti-
TNFα medications take on a greater importance to women 
with inflammatory arthritis. Fortunately, up to 75% of women 
with RA will improve during pregnancy, with half of them 
having mild disease.8,9 However, half of women remain 
with moderate to severe RA activity throughout pregnancy. 
Women with psoriatic arthritis and ankylosing spondylitis do 
not generally improve during pregnancy. For these women, 
pregnancy can be a debilitating period marked by worsening 
joint pain, inflammation, and damage.
A high degree of inflammatory joint activity may pro-
mote an early delivery of a small infant.10 Up to a quarter 
of women with RA will deliver preterm and the average 
birth weight, even for full-term infants, is lower than in 
healthy controls.11 In addition, continuing joint disease dur-
ing pregnancy can lead to disability, pain, and further joint 
damage. For women with high levels of disease activity 
during pregnancy, anti-TNFα medications may be the best 
option for therapy.
Maternal risks from anti-TNFα 
medications
The risk for reactivation of tuberculosis is the primary 
infection concern for anti-TNFα medications. TNFα is an 
important cytokine for the maintenance of the granuloma 
that contains a prior tuberculosis (TB) infection. When 
TNFα is blocked effectively by these drugs, the granuloma 
may disintegrate, allowing the TB to reinfect the lungs or 
extra-pulmonary areas. A recent study of over 10,000 patients 
treated with anti-TNFα medications compared to over 3000 
RA patients without anti-TNFα medications from the Brit-
ish Society for Rheumatology Biologics Register (BSRBR) 
demonstrated a significant risk for TB reinfection.12 The 
risk of TB was 144 events/100,000 patient years for adali-
mumab, 136 events/100,000 patient years for infliximab, 
and 39 events/100,000 patient years for etanercept. Patients 
from areas with endemic TB are at highest risk. All patients International Journal of Women’s Health 2010:2 201
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should have tuberculosis screening prior to the initiation of 
any anti-TNFα medication.
Most experts cite a doubling of the risk of infection for 
patients on anti-TNFα medications. A review of the BSRBR, 
however, did not find an increase in serious infections for 
patients on anti-TNFα medications, though these patients did 
have a higher risk of skin and soft tissue infections.13 A meta-
analysis of 5 studies infliximab for RA found no increase in 
serious infections infections (relative risk [RR] 0.96).14 A meta-
analysis of all anti-TNFα medications for psoriatic arthritis 
also found no increase in serious side effects or infection.15 
Despite these reassuring findings, it is essential to remain 
vigilant for infection in all patients on these medications. 
Pregnancy is a time of relative immunosuppression, so prompt 
evaluation and treatment of potential infection is important.
The injectable anti-TNFα medications may cause tran-
sient injection site reactions with swelling, erythema, and 
pruritis. These typically resolve within a week and rarely 
dose-limiting. Infliximab infusions can be accompanied by 
an infusion reaction, worsened by human-anti-chimeric anti-
bodies (HACA). These antibodies are more prone to develop 
when a patient is not co-treated with methotrexate. HACA 
can also decrease the clinical benefit of infliximab. An infu-
sion reaction is more likely if a patient has had a significant 
break between infusions. This poses a problem for infliximab 
use in pregnancy: methotrexate is contraindicated and many 
women will elect to stop use during pregnancy. When the 
drug is restarted post-partum, the risk for infusion reaction 
is high. This risk may be modified by skipping the loading 
dose and aggressive use of pre-medications.
The extent to which anti-TNFα medications increase 
the risk for malignancy remains under debate. All patients 
with rheumatoid arthritis are at increased risk, particularly 
for lymphoma. A recent meta-analysis of etanercept showed 
no increase risk in RA patients treated with the drug vs 
placebo.16 A prospective cohort of over 10,000 RA patients 
also found no increase in lymphoma among patients treated 
with anti-TNFα medications compared to those on other 
disease modifying drugs.17 The absolute risk of malignancy 
in these patients remains very low.
There are several other, more rare, complications that may 
be associated with anti-TNFα medications. Demyelinating dis-
orders was identified when a trial of an anti-TNFα medication 
for multiple sclerosis (MS) found an increase in new lesions 
on the drug compared to placebo. Fewer than 200 cases of new 
MS-like disease have been reported.18 Drug-induced lupus can 
occur rarely following anti-TNFα medications. Many patients 
will develop a positive ANA antibody and even positive 
anti-dsDNA antibody, but only an estimated 0.1%–0.3% will 
acquire symptoms of lupus.18 Pustular psoriasis may paradoxi-
cally develop during anti-TNFα medication therapy.
Transplacental passage  
of immunoglobulins
Infants are protected from infectious diseases in the first 
months of life by the maternal antibodies that cross the 
placenta in the latter half of pregnancy.19 Antibody transfer 
across the placenta does not begin until the second trimester, 
but then increases in a linear fashion until delivery. At term, 
the amount of maternal IgG antibody is higher in the neonate 
than in the mother. This pattern holds when the IgG antibody 
is an anti-TNFα medication. A specific Fc receptor neonate 
(FcRn) facilitates transfer of the IgG antibodies across the 
syncytiotrophoblast into fetal circulation.19
Transplacental transfer  
of anti-TNFα medications
A small study of pregnant rats found that a murinized 
TNFα inhibitor on a PEGylated Fab fragment (similar to 
Table 1 The TNF inhibitor medications
Drug name and  
manufacturer
FDA  
indications
FDA  
pregnancy class
Estimated  
half-life
Type  
of antibody
Infliximab (Remicade®; Centocor) rA,   AS, PsA, CD, US, PP B 9–10 days Chimeric monoclonal IgG1 antibody
Etanercept (Enbrel®;   Amgen) AS, PsA, PP,  JIA B 3 days TNF receptor linked to the Fc portion  
of human IgG1
Adalimumab (Humira®;   Abbott) AS, PsA, CD, PP,  JIA B 10–13 days recombinant monoclonal IgG1 antibody
Certolizumab (Cimzia®; UCB) rA, CD B 14 days Pegylated humanized antibody Fab’ fragment  
of TNF-alpha monoclonal antibody
Golimumab (Simponi®;  
Centocor Ortho Biotech)
rA,   AS, PsA B 7–20 days Human monoclonal IgG1 antibody
Abbreviations: rA, rheumatoid arthritis; AS, ankylosing spondylitis; PsA, psoriatic arthritis; CD, Crohn’s disease; UC, ulcerative colitis; PP, plaque psoriasis; JIA, juvenile 
idiopathic arthritis.International Journal of Women’s Health 2010:2 202
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certolizumab) had less placental and milk transfer than a 
murinzed TNFα-inhibitor in the form of IgG1.20 All 5 rats 
treated during pregnancy with the PEGylated form had no 
or minimal (0.5% of maternal levels) transfer into the fetal 
circulation 7 days later. The half-life of the drug, however, was 
noted to be very short and TNF levels were not reported. In 
contrast, the IgG1 form was found in all rats at a mean 15.6% 
of maternal concentration. There appeared to be higher levels 
of the IgG1 than the PEGylated form in the breastmilk of 
rats treated during pregnancy. These rats were not, however, 
treated post-partum with either medication. This report is 
limited in several ways: most importantly, TNF levels were 
not measured. The PEGylated form has a shorter half-life so 
the fetus may have a shorter window of exposure but may 
have an extended period of drug effect. In addition, these 
are murine data using drugs that are modified for use in rats, 
making it difficult to extrapolate to humans.
Infants exposed to infliximab in the weeks prior to deliv-
ery will likely be born with serum infliximab levels similar to 
their mother. Maternal and fetal infliximab serum levels have 
been monitored in several small studies. One case report of a 
35-year-old woman who received infliximab 10 mg/kg every 
6 to 8 weeks throughout pregnancy (including 2 days prior 
to delivery) for severe Crohn’s disease reported high levels 
of infliximab in the infants’ serum 6 weeks after delivery.21 
At 6 weeks, the mother and infant had the same amount of 
infliximab in the serum, despite the mother having received 
another 10 mg/kg dose after delivery. From that point on, 
the mother’s levels fluctuated with infliximab therapy but 
the infant’s levels fell slowly over the next 6 months, despite 
breastfeeding.
Pregnancy outcomes  
with exposure to anti-TNFα 
medications
For the purposes of this report, pregnancies will be grouped 
according to the anti-TNFα medications utilized in preg-
nancy. The largest report of pregnancies exposed to anti-
TNFα medications, however, does not include data about 
which anti-TNFα medication was used. From a survey 
completed by rheumatologists, 454 pregnancies in women 
with RA were identified. The anti-TNFα medication was 
continued throughout pregnancy in 31% of these.22 Preg-
nancy results were available for 417 pregnancies, of which 
378 (90%) were normal deliveries, 9 were premature, 
5 electively terminated, and 25 (6%) ended in a miscarriage. 
Though none were reported to have congenital anomalies, 
3 were born with ‘medical problem(s) due to’ the anti-TNFα 
medications.22
Infliximab
A large collection of TNF-inhibitor exposed pregnancies 
from the Centocor safety database was reported in 2004.23 
Pregnancies were collected in two ways: 1. self-reported to 
the company by a physician or patient and 2. pregnancies 
that occurred within clinical trials (21 pregnancies). This 
report includes 96 pregnancies with direct exposure and 
known pregnancy outcomes. Exposure was remote (none 
within 3 months of pregnancy) in 7% of pregnancies, but the 
remaining pregnancies were exposed either within 3 months 
of conception (26%) and/or during the first trimester (60%). 
None of these pregnancies appear to have been exposed in 
the second or third trimesters, though timing of exposure is 
unknown in 6. Of the 96 pregnancies, 19% were electively 
terminated, 15% ended with a pregnancy loss, most in the 
1st trimester, and 66% resulted in a live birth. Of these, 2 
infants had congenital anomalies: 1 tetralogy of Fallot and 
1 with intestinal malrotation, both after the first trimester 
infliximab exposure.
Four case reports of women with Crohn’s disease with 
infliximab use during pregnancy have been reported. One 
reported a woman receiving infliximab at the time of con-
ception for colonic Crohn’s with a rectovaginal fistula who 
did not continue the drug during pregnancy, though she did 
take mesalamine, metronidazole, and azathioprine. Unfortu-
nately, her baby was delivered at 23 weeks gestation and died   
3 days later with cerebral and pulmonary hemorrhage.24 Three 
other cases have happier outcomes: 1 continued infliximab 
throughout pregnancy and delivered without complications 
at 36 weeks gestation.25 Another received 2 doses of 5 mg/kg 
infliximab 1 and 3 weeks after conception and delivered 
a healthy baby at term.26 Another woman with fistulizing 
peri-anal disease received 500 mg infliximab 3 days after 
conception. Her pregnancy was complicated by a small 
bowel obstruction at week 17, but she delivered a healthy 
baby at 36 weeks gestation.27 One case of a pregnancy in a 
woman with rheumatoid arthritis on infliximab resulted in 
a full term birth.28
A woman with rheumatoid arthritis with a complicated 
pregnancy history had a miscarriage on infliximab. Her first 
4 pregnancies resulted in a stillbirth due to an acute hypoxic 
event at 36 weeks, a miscarriage at 15 weeks, and 2 healthy 
infants born preterm at 34 weeks and 35 weeks. Her final 
pregnancy resulted in a miscarriage at 6 weeks. She was tak-
ing methotrexate 20 mg per week, folic acid 5 mg per week, International Journal of Women’s Health 2010:2 203
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diclofenac and infliximab 3 mg/kg every 8 weeks at the time 
of conception of this final pregnancy.29
Etanercept
The OTIS registry is a prospective cohort study of pregnant 
women with inflammatory arthritis including rheumatoid 
arthritis, ankylosing spondylitis, and psoriatic arthritis. This 
registry reported 100 pregnancies exposed to etanercept, 
compared to 54 disease controls, in an abstract in 2008.30 The 
timing and duration of etanercept exposure was not reported. 
The etanercept and control pregnancies had similar live birth 
rates: 94% with etanercept vs 87% for controls. The rate of 
major congenital anomalies was also similar, with 8% after 
etanercept exposure and 5.7% without it. The 8 anomalies 
after etanercept included one each of congenital hypothy-
roidism, microcephaly, pyloric stenosis, cystic adenomatoid 
malformation, and hypospadias. In addition, one child had 
esotropia, an inguinal hernia, and an atrial septal defect. One 
child had displacement of the stomach, epispadias, and retinal 
abnormalities. One child had a ventricular septal defect and 
mild peripheral pulmonic stenosis. In the control group, 2 
infants had Down’s syndrome and 1 had a duplex kidney. The 
authors concluded that these data did not raise a significant 
concern about the safety of etanercept in pregnancy.
Eight pregnancies exposed to etanercept for rheumatoid 
arthritis, collected by survey from rheumatologists across 
the United States, resulted in 6 full-term deliveries, one 
spontaneous abortion (also exposed to methotrexate), and 
one elective termination.28
A 40-year-old woman with RA and 2 prior 1st trimester 
miscarriages conceived while taking etanercept and con-
tinued the drug through pregnancy and lactation. Maternal 
serum levels of the drug remained stable throughout, ranging 
from 2239 ng/mL at the time of delivery to 3849 ng/mL in 
the first trimester. The cord blood contained 81 ng/mL of 
etanercept, a level almost 30-fold lower than in the maternal 
serum at the time.31 By 1 week post-partum, the baby’s etan-
ercept level had fallen to 21 ng/mL, by week 3 to 2 ng/mL, 
and it was undetectable by week 12, despite breastfeeding 
exclusively.
Adalimumab
In 2008, OTIS presented data on adalimumab at the Ameri-
can College of Rheumatology national scientific meeting.32 
This report included 30 adalimumab-exposed RA pregnan-
cies, compared with 53 RA patients without medications 
and 40 healthy pregnancies. All adalimumab exposure was 
limited to the first trimester. Each group has similar rates 
of live birth (90%–91%). Preterm birth was most common 
in the RA control group (19%), second most common in 
the adalimumab group (11%), and there were no preterm 
births in the healthy control group. Congenital anomalies 
were noted in 2 adalimumab exposed babies (1 with unde-
scended testicle and 1 with microcephaly), compared to 
1 chromosome abnormality in the RA control group and 
2 major defects identified in the healthy controls. A larger 
case-series of pregnancies exposed to adalimumab either for 
reasons other than RA or that were reported retrospectively 
included 58 pregnancies, of which 10% had major malfor-
mations: 3 chromosome abnormalities, 1 spina bifida with 
hydrocephalus, 1 ventricular septal defect, and 1 congenital 
hip dysplasia with inguinal hernia.
Four case reports of adalimumab in pregnancy have been 
reported, all with good maternal and fetal outcomes. Two 
reports include 34- and 35-year-old women with ileocolonic 
Crohn’s diseases on adalimumab prior to conception and 
continuing throughout the pregnancy and lactation. On this 
medication, one woman’s Crohn’s disease became well con-
trolled and she was able to taper her prednisone. The other had 
a flare at 20 weeks gestation that was treated with additional 
steroids. Both pregnancies were uncomplicated, with babies 
born at term, with normal growth at 6 months of age.33,34 A 
third woman with Crohn’s disease was started on adalimumab 
and azathioprine at 19 weeks pregnancy for a severe flare. 
Within 2 weeks she was feeling better and after 3 months 
she was able to taper off prednisone. The baby was born at 
term and was doing well 1 year later.35 A young woman with 
Takayasu’s arteritis complicated by multiple arterial stenoses 
in major vessles was on adalimumab 40 mg every 4 weeks 
and leflunomide 10 mg a day at conception. On discovery of 
the pregnancy at 8 weeks the leflunomide was stopped but 
the adalimumab was continued with low dose prednisone 
and dalteparin. The baby was delivered at term via cesarian 
section without complication.36
Certolizumab
Certolizumab was FDA approved for Crohn’s disease and 
inflammatory arthritis in 2008, leaving little time for the col-
lection of pregnancies at this point. However, 2 cases have 
been reported. A 22-year-old woman with Crohn’s disease 
received 9 injections of certolizumab prior to pregnancy and 
one injection in the first trimester. She felt well and discon-
tinued the drug until she had a flare at 31 weeks gestation. 
At that time she received 1 injection of the drug to treat a 
flare and felt better. She delivered her baby at term without 
complication.37International Journal of Women’s Health 2010:2 204
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A second case of a 22-year-old women with Crohn’s 
disease who started certolizumab 400 mg subcutaneously in 
the second trimester and continued it every 4 weeks through 
the end of pregnancy. Her last dose was 2 weeks prior to 
delivery. She delivered a healthy baby at 37 weeks gestation. 
The certolizumab level at delivery was 18.83 µg/mL and in the 
cord blood was 1.65 µg/mL. This appears to demonstrate that 
the level of certolizumab that crosses to fetal circulation may 
be more limited than with some other TNFα-inhibitors.38
Golimumab
There are no reports of human pregnancies exposed to 
golimumab in the literature at this time. A study of the drug 
in macaque monkeys, however, provides interesting data. 
Pregnant monkeys were studied over two separate time peri-
ods: first trimester with exposure to 25 mg/kg, 50 mg/kg, or 
placebo twice a week from gestational day (GD) 20 to 50; and 
later in pregnancy with the same dosing given from GD50 
through lactation day (LD) 33.39 The typical human dose is 
100 mg every 4 weeks, making the doses in this study at least 
40-fold higher than would be used clinically.
After first trimester exposure, the pregnancies were ter-
minated at GD100 for anatomic and immune analysis. At 
this time point, there were no differences in the number or 
distribution of B and T cells in lymphoid tissue or between 
percentages of lymphocyte subsets in any of the treatment 
groups. The fetal serum level of golimumab was, on average, 
half that of the mother.
For the second group with exposure later in pregnancy, 
each monkey delivered naturally and all infants were 
breastfed. Pregnancy loss occurred in 3 control preg-
nancies and in 3 with 50 mg/kg dosing. Neonatal death 
occurred within 2 weeks of delivery for 2 preterm infants, 
one in the 25mg/kg group and one in the 50 mg/kg group. 
At birth, there was no difference in weight or anatomy in 
the treatment groups. Humeral immunity and delayed type 
hypersensitivity in response to tetanus toxoid was the same 
in each group. Finally serum levels in the mother, infant, 
and milk were all measured and showed a dose response 
(see Table 2).
Possible association between  
anti-TNFα medications  
and VACTERL association
Some concern has been raised that the use of TNF dur-
ing pregnancy may increase the incidence of VACTERL 
association.40,41 VATER or VACTERL association (as it is 
labeled in 2 articles by the same team) is a non-random 
collection of congenital anomalies that include a wide 
range of systems (VATER association: Vertebral, Anal, 
Tracheal, Esophageal, and Radius or Renal; VACTERL 
association: Vertebral, Anal, Cardiac, Tracheoesophageal, 
Renal, and Limb). There may be a genetic defect causing 
a small number of cases, but most appear to be sporadic 
and without known cause.42 This concern was triggered by 
a baby born with VATER association after exposure to 50 
mg twice a week of etanercept throughout pregnancy for 
psoriatic arthritis in the mother. This baby was born with 
multiple anomalies, including tracheal atresia and tracho-
esophageal fistula, esophageal atresia, imperforate anus, a 
T12 vertebral anomaly, a patent foramen ovale, hypospadias, 
and spina bifida occulta. In a 2006 report of this pregnancy 
and offspring, the authors postulate a connection between 
anti-TNFα medications, and etanercept in particular, in 
triggering these anomalies based on similar anomalies 
found an a knock-out TRAF4 mouse.40 This mouse lacks 
TNF receptor associated factor 4 (TRAF4) and some of the 
offspring have tracheal atresia, pulmonary inflammation, 
vertebral anomalies, and spina bifida.
To determine whether this case was isolated or not, the 
same authors requested the list of adverse events reported 
to the FDA for anti-TNFα medications and identified 61 
congenital anomalies out of over 120,000 events. This 
database included all reports between when anti-TNFα 
medications were first commercially available to Decem-
ber of 2005. The majority of this time, only infliximab 
and etanercept were available, with adalimumab approved 
December 31, 2002. Of these 61 anomalies, 7 were from 
the index case reported above, leaving 54 other anomalies 
in 40 babies.41
The authors then took a somewhat unorthodox leap to 
determine the number of anomalies out of the 54 that could 
be included in the VACTERL association. In this calculation, 
they included all heart defects (n = 9), kidney (n = 3), limb 
Table 2 Golimumab concentrations in the maternal serum and 
milk and infant serum39
Maternal  
serum
Milk Infant 
serum
After  
1st  
dose
After   
last  
dose
LD14 LD28 LD15a
25 mg/kg twice  
per week
176  
µg/mL
851  
µg/mL
0.75  
µg/mL
0.79  
µg/mL
219  
µg/mL
50 mg/kg twice  
per week
321  
µg/mL
1482  
µg/mL
3.65  
µg/mL
3.62  
µg/mL
534  
µg/mL
aSome infants had detectable golimumab up to 6 months following birth.International Journal of Women’s Health 2010:2 205
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(n = 3), and tracheal (n = 2) abnormalities. They also included 
2 cases of hypospadius, 2 cases with lung malformations, a 
case with intestinal malrotation, and an infant with trisomy 18 
as infants with components with the VACTERL association. 
They determined that 56% of the reported anomalies were 
consistent with those found in VACTERL association.
In addition, the authors compared the relative frequency in 
the reported anomalies from the FDA database to the relative 
frequency of congenital anomalies in the general population. 
Using this method, they concluded that several anomalies 
were found more commonly than anticipated, including pul-
monary malformation (n = 3), cystic kidney (n = 3), teratoma 
(n = 3), atrial septal defect (n = 2), tracheal stenosis (n = 2), 
Duane’s syndrome (n = 1), ventricular hypokinesia (n = 1), 
and optic neuropathy (n = 1).
This reported connection between VACTERL asso-
ciation and anti-TNFα medications is tenuous, at best. 
A very critical editorial was written by the directors of the 
Motherrisk Program in Canada and published in the same 
edition of the Journal of Rheumatology in which this paper 
appeared.43 These editorialists point out numerous problems 
with the methodology including the assumption that the 
spontaneous reports to the FDA could be extrapolated to 
the general population, the bias towards reporting for babies 
with anomalies following a drug exposure compared to an 
anomaly following a more normal pregnancy, and skepti-
cism of the validity of VACTERL as an association related 
to drugs. These authors also cite several reports of other 
medications initially thought to be associated with anomalies 
from studies of similar method to this VACTERL study that 
were later proved to be incorrect by prospective studies.
Other problems with this study include the lack of a 
denominator, the number of pregnancies exposed to anti-
TNFα medications, making it impossible to determine 
whether the overall or specific rate of anomalies is greater 
than would be expected. In addition, the data available about 
each anomaly vary widely, making the classification of each 
anomaly difficult. Having one anomaly that could be a part 
of VACTERL association does not provide a diagnosis of this 
association. We expect that the etiology of the many different 
cardiac anomalies, for example, may vary widely. This report, 
however, ventures to lump them all together into one cause. 
Finally, drawing conclusions about the relative frequency of 
anomalies, when many have only been reported one time, 
is problematic. The laws of probability demand that some 
anomalies occur and that some be rare in any large group 
of pregnancies. Having one reported case of a rare anomaly 
does not lead to causation.
In summary, the report of VATER association in one infant 
after high dose etanercept exposure is interesting. The data 
that suggest this is a systemic problem with anti-TNFα medi-
cations are weak and not supported by prospective studies.
Use of anti-TNF medications  
in fertility therapy
In some reproductive immunology clinical practices anti-
TNFα medications have been used to promote fertility. 
The theory behind this is controversial, but hinges on the 
overproduction of TNFα in the uterine lining by NK cells, 
thought to impair implantation. Two retrospective, non-ran-
domized studies have shown improvements in live birth rates 
when including an anti-TNFα medication in therapy around 
conception. The first study included 75 women with recurrent 
miscarriage.44 The live birth rate for women treated at the 
time of conception with an anti-TNFα medications (etaner-
cept or adalimumab from 30 days prior to conception until 
fetal cardiac activity was identified by ultrasound) plus IVIg 
and low-molecular weight heparin had a higher live birth 
rate (71%) than women treated only with anticoagulation 
(19% live birth rate) or women treated with anticoagulation 
plus IVIg (54% live birth rate). The average gestational age 
of live births was similar between all groups (ranging from 
37.2 to 38.8 weeks). One baby exposed to anticoagulation 
and IVIg was born with Down’s syndrome; the remaining 
babies were born without congenital anomalies.
A second study by the same authors included another 
75 women with Th1/Th2 cytokine elevation treated with vari-
ous therapies, including adalimumab 40 mg 2 to 4 times prior 
to conception with IVIg (intravenous immunoglobulin), IVIg 
alone, adalimumab alone, or no therapy.45 Therapy was not 
randomized, but based on clinical decision. IVIg was admin-
istered at 400 mg/kg once during the IVF cycle and during 
the first trimester of pregnancy. The results of the study were 
dramatic, with no untreated cycle resulting in a pregnancy or 
live birth compared to 73% of cycles resulting in a live birth 
after adalimumab and IVIg (see Table 3). A separate abstract 
by the same authors found no increase in congenital anomalies 
in pregnancies exposed to adalimumab pre-conception (2% – 1 
report of Di George Syndrome, a chromosome 22 deletion), 
compared to IVIG (3%) or no immunotherapy (2%).46
There are several problems with these studies and 
the use of anti-TNFα medications is not widely accepted 
in the reproductive endocrinology field. For the second 
study, the immunologic and clinical benefit of adalimumab 
given 2 months prior to embryo transfer is unclear. While 
the authors report that this treatment significantly altered International Journal of Women’s Health 2010:2 206
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ratios of TNFα:Il-10 and IFNγ:IL-10 2 months prior to 
transfer, this is not documented at the time of embryo 
transfer. Measuring NK cells and these cytokine levels 
is not standardized and only performed in specific labs. 
These studies were not randomized and it is not clear how 
therapy was determined or how patients were selected for 
this retrospective review. In particular, the abstract with 
birth defect information contains many more pregnancies 
with IVIG alone and no therapy than are included in the 
other published reports. A randomized trial will be required 
to confirm these findings.
Anti-TNFα medications  
and male fertility
TNFα may be important both in promoting and impairing 
sperm production and motility. TNFα may inhibit germ cell 
apoptosis in seminferous tubules, a function that may be 
lost in rats by infliximab.47 In addition, the extrusion of the 
cytoplasm that must take place in the development of the 
spermatozoa may be regulated by TNFα.47 On the other hand, 
elevated levels of TNFα have been found in the semen of men 
with genital tract infections.48 Also high levels of TNFα may 
interfere with sperm binding to the zona pellucida.48
Several studies have sought to determine the impact 
of anti-TNFα medications on sperm viability. One study 
exposed human sperm samples to increasing levels of TNFα 
with or without infliximab. They found that sperm motility 
and sperm DNA damage both worsened with TNFα, but 
this was largely prevented by co-incubation with inflix-
imab.48 Another study compared semen samples in men 
with inflammatory bowel disease before and after infliximab 
therapy.47 Seven of these men were taking ongoing therapy, 
so it is unclear how unaffected the initial sperm collection 
might be from prior infliximab treatments. This study found 
that infliximab may modestly diminish sperm motility and 
morphology; however given the small number of subjects and 
the inherent variability in sperm analysis, this finding is not 
conclusive. The authors do not recommend discontinuing inf-
liximab therapy unless male-factor infertility is identified.
A total of 17 pregnancies conceived by men taking inf-
liximab have been reported.23,49,50 Fifteen of the men received 
infliximab within 3 months of conception; for the remaining 2 
the relationship between timing for conception and infliximab 
was unknown. One pregnancy resulted in a first trimester 
miscarriage in a woman with Addison’s disease and a prior 
miscarriage. The remaining 14 pregnancies resulted in healthy 
babies. One of these reports, as well as a report of a pregnancy 
conceived by a father on etanercept, suggest that the anti-TNFα 
medications promoted male fertility.50,51 In both of these reports 
the men were taking sulfasalazine, a drug well documented 
to diminish sperm number and motility, when prior sperm 
samples were analyzed. Both pregnancies, however, were 
conceived within several weeks of anti-TNFα medication 
initiation, suggesting either an improvement of sperm function 
or increased sexual activity following therapy.
Anti-TNFα medications  
in breastmilk
Absorption of maternal antibodies through the breastmilk is 
limited in humans.19 The predominant immunoglobulin in 
human breastmilk is IgA, which provides mucosal immunity in 
the gut of the infant. Little IgG or other large immunoglobulins 
cross into breastmilk and these do not enter infant circulation in 
significant amounts. For this reason, we would expect that the 
transfer of the IgG anti-TNFα medications would be minimal, 
as well. There are limited clinical data that support this theory 
(see Table 4). Half a dozen case reports of women receiving IV 
infliximab for the treatment of Crohn’s disease have not shown 
any transfer of this drug into the milk in women breastfeeding 
their infants. The timing of milk and serum assessment varies, 
but whether measured within 24 hours or 30 days of dosing, 
each sample has been negative. One report of a woman with 
RA breastfeeding an infant while taking etanercept found a 
minimal level of etanercept in the breastmilk (3.5 ng/mL) at a 
time when the maternal serum level was 2872 ng/mL, a transfer 
rate of about 0.1%.31 After exposure in utero, the infant had 
falling levels of etanercept from week 1 to week 3, probably 
reaching an undetectable level by week 4 or 6 post-partum, 
though a repeat measure was not performed until week 12. Two 
cases have been reported of women treated with anti-TNFα 
Table 3 results of a non-randomized trial of adalimumab with or 
without IvIg with in vitro fertilization in women with an elevated 
Th1:Th2 cytokine ratio45
Group 1 Group 2 Group 3 Group 4 P value
Treatment Adalim-
umab  
plus IVIg
IVIg Adalim-
umab
No  
treatment
Number  
of cycles
41 23 6 5
Number  
of prior failed 
IvF cycles
1.7 ± 1.8 0.8 ± 1.2 1.2 ± 1.6 1.6 ± 1.7 0.20
Number  
of embryos 
transferred
2.1 ± 0.3 2.0 ± 0.2 2.2 ± 0.4 1.8 ± 0.4 0.07
Live birth rate 73% 52% 50% 0 0.003International Journal of Women’s Health 2010:2 207
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medications post-partum who were not actively breastfeed-
ing for over 1 month, but had residual lactation.55,56 In each 
of these cases, the anti-TNFα medication (etanercept in one, 
infliximab in the other) was measurable in the excreted milk 
3 to 4 months post-partum. It is likely that the milk ducts 
were more porous in these two women who were not actively 
breastfeeding, allowing these large molecules to pass.57 It is 
reassuring that the women breastfeeding their children had no 
or minimal anti-TNFα medication excreted into milk.
A study of pregnant and lactating rats compared TN3 
PEGylated Fab’ (comparable to certolizumab) and TN3 IgG1 
antibody (comparable to the classic anti-TNFα medication 
IgG1 molecules).20 In the rats treated with the PEGylated 
molecule, milk levels contained about 5% of the maternal 
serum level and the infant’s serum level was undetectable. 
Following TN3 IgG1 treatment, the milk contained 24% of 
the maternal plasma level and the infant serum level was actu-
ally higher than the maternal level. The drug was only given 
prior to delivery, so it is likely that much of this high IgG1 
level in the offspring was from transplacental transfer.
While more reports of anti-TNFα medication levels in 
human breastmilk would be helpful, particularly for drugs 
other than infliximab, the data thus far are reassuring.
Treatment recommendations
The data presented in this review are, at times, conflicting and 
always limited in power. It is necessary, however, to draw some 
clinical conclusions for our patients. The overriding principle in 
determining medication use during pregnancy is balancing the 
risks of no therapy to the mother and fetus vs the risks of therapy. 
For some diseases, in particular active Crohn’s disease, the risk 
of very active disease far outweighs the risk of anti-TNFα medi-
cations. For other diseases, such as rheumatoid arthritis which 
often improves during pregnancy and activity has little impact 
on pregnancy outcomes, the balance may be different.
Pre-conception
It is hypothesized that the anti-TNFα medications do not cross 
to the fetus in the first trimester. For this reason, it may not be 
unreasonable to allow women to continue to use these medi-
cations until the time of conception. Pregnancy termination 
after a first trimester anti-TNFα medication exposure without 
evidence of a congenital anomaly is not recommended.
During pregnancy
For women with rheumatoid arthritis, holding the anti-TNFα 
medication when pregnancy is discovered is often well toler-
ated. Many women improve during pregnancy and are able 
to bear this drug holiday. Others are able to live with moder-
ate inflammatory arthritis with low dose prednisone and/or 
sulfasalazine or hydroxychloroquine. For women with a his-
tory of severe erosive disease or who flare during pregnancy, 
consideration can be made for continuing (or restarting) the 
anti-TNFα medication during the pregnancy.
Table 4 TNF use during lactation: level of TNF in maternal serum and milk, and infant serum
Maternal  
disease
TNF-therapy Maternal  
serum levels
Milk  
levels
Infant serum  
levels
Kane52 Crohn’s  
Disease 29 y/o
Infliximab D/C dose at  
31 weeks. restart ppd#3
74.27 µg/mL Undetectable Not collected
Crohn’s  
disease 32 y/o
Infliximab D/C week 32.  
restart ppd#10
62.62 µg/mL Undetectable Undetectable
Crohn’s  
disease 24 y/o
Infliximab dosed week  
19, 21, 25. restart ppd#14
59.97 µg/mL Undetectable Undetectable
Peltier53 Crohn’s  
disease
Infliximab 5 mg/kg Not collected None detected  
at 24 h and 1 week  
after infusion
Not collected
Stengel54 Crohn’s  
disease
Infliximab 10 mg/kg q  
4 weeks
Not collected None detected in  
daily collections x30
Not collected
vasiliauskas21 Crohn’s  
disease 32 y/o
Infliximab 10 mg/kg – dose  
2 wk predelivery, also  
with lactation
Not reported  
in abstract
Undetectable 39.5 µg/mL 6 wk post-partum,  
slowly declined over 6 months
Murashima31 rheumatoid  
arthritis 40 y/o
etanercept 25 mg sq  
twice per week
2239 ng/mL at  
delivery 2872 ng/mL  
at time of breastmilk  
collection
3.5 ng/mL 81 ng/mL cord blood. 21 ng/mL  
1 week postpartum 2 ng/mL  
3 weeks postpartum; undetectable     
12 weeks postpartum
Abbreviations: D/C, discontinued; y/o, year old; ppd, post-partum day.International Journal of Women’s Health 2010:2 208
Clowse Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
For women with ankylosing spondylitis or psoriatic 
arthritis, pregnancy is rarely accompanied by remission. For 
these women, continuation of the anti-TNFα medication, per-
haps with less frequent dosing, through pregnancy may make 
this period less painful. Prior to continuing the anti-TNFα 
medication, however, the risks and benefits, including the 
uncertainty about these medications, must be discussed.
The recommendations of the European Crohn’s and Colitis 
Organization state that “the greatest risk to mother and fetus 
during pregnancy is active disease, and not the medication used 
to treat it”.58 They recommend continuing anti-TNFα therapy 
for women with Crohn’s disease due to the high risk of relapse 
and ensuing pregnancy complications. They recommend dis-
continuing the anti-TNFα medication in the middle of the third 
trimester, however, to diminish the exposure to the fetus prior to 
delivery. Due to the high rate of IgG transfer near term, babies 
have been found to have similar blood levels of infliximab to 
the mother. By discontinuing this drug 8 to 10 weeks prior to 
delivery, the baby will likely be born with no or minimal serum 
levels, thus avoiding immunosuppression in a young infant.
Though there are some suggestive data that certolizumab 
does not cross the placenta as easily as the IgG derived drugs, this 
is still a preliminary finding that has not been well confirmed.
Breastfeeding
Data from actively breastfeeding patients confirms that low 
levels of IgG anti-TNFα medication transfer into human 
milk. The number of patient reports, however, is limited. 
After discussion of the risks and benefits, some patients 
decide to restart anti-TNFα medication following delivery. 
This can be particularly beneficial in women with rheumatoid 
arthritis who will often flare in the weeks following delivery. 
By restarting an anti-TNFα medication soon after delivery, 
this flare may be avoided.
Summary
Though the human clinical data on the use of anti-TNFα 
medications during pregnancy and lactation are limited, what 
is available is reassuring. Despite the collection of congenital 
anomalies reported to the FDA, prospective cohorts of exposed 
pregnancies have not found an increased rate of anomalies. 
In utero exposure, particularly close to delivery, may result in 
an infant born with anti-TNFα medications detectable in the 
serum. For this reason, it may be prudent to discontinue the 
drug several half-lives prior to expected delivery. In addition, 
these infants should be monitored closely for infection. It is 
important that all women who take anti-TNFα medications 
during or following pregnancy understand the potential risks 
as well as the absence of confirmatory data demonstrating 
the safety of these drugs. In women with severe inflamma-
tory disease that cannot be managed with better documented 
medications, however, anti-TNFα medications may improve 
the health of the mother, and thus the fetus.
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